Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM580GT)

Drug Name
Xanamem Drug Info
Synonyms
Xanamem; UE2343; 1346013-80-6; (5-(1H-Pyrazol-4-yl)thiophen-3-yl)((1R,3r,5S)-3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone; starbld0030988; SCHEMBL23207782; SCHEMBL23798797; GTPL12037; GLXC-26582; compound 4 [PMID: 28012176]; UE-2343; [(1S,5R)-3-hydroxy-3-pyrimidin-2-yl-8-azabicyclo[3.2.1]octan-8-yl]-[5-(1H-pyrazol-4-yl)thiophen-3-yl]methanone
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1/2 [1]
Cross-matching ID
PubChem CID
137530063
TTD Drug ID
DM580GT

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) TTN7BL9 DHI1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DTT HSD11B1 10.967 5.178 5.865 6.377
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DTT HSD11B1 2.03E-01 -0.01 -0.08
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04983368) XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem? in Healthy Elderly Volunteers. U.S.National Institutes of Health.
2 Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem?). Br J Pharmacol. 2017 Mar;174(5):396-408.